Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c &lt;7%

P. Cannon, Christopher; Perkovic, Vlado; Agarwal, Rajiv; Baldassarre, James; L. Bakris, George; M. Charytan, David; de Zeeuw, Dick; Edwards, Robert; Greene, Tom; J.L. Heerspink, Hiddo; Jardine, Meg; Levin, Adeera; Li, Jing-Wei; Neal, Bruce; A. Pollock, Carol; C. Wheeler, David; Zhang, Hong; Zinman, Bernard; W. Mahaffey, Kenneth

doi:10.1161/circulationaha.119.044359

Public

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%

Published in Circulation • Nov 11, 2019

Authors:

Christopher P. Cannon

Vlado Perkovic

Rajiv Agarwal

Abstract

canagliflozin chronic kidney disease diabetes mellitus, type 2 SGLT2 inhibitors T raditional management of diabetes mellitus has focused on glycemic control, beginning with lifestyle changes, followed by metformin, and then other classes of antiglycemic agents. 1 Sodium glucose co-transporter 2 inhi...

Subject

Medicine

Canagliflozin

Diabetes mellitus

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!